论文部分内容阅读
目的分析肺癌化疗后应用升白细胞药物不同时机患者的感染及白细胞下降情况,探讨化疗后应用升白细胞药物的合适时机。方法选取98例肺癌化疗后病人,随机分组,A组(50例)化疗后第2天开始、B组(48例)化疗后1周开始应用重组人粒细胞集落刺激因子(G-CSF),观察2组2周内合并感染及白细胞下降情况。结果(1)化疗后立即应用升白细胞药的A组感染发生率明显低于化疗后1周应用的B组(10.0%vs39.6%,P<0.05);白细胞<3×109/L发生率明显低于B组(8.0%vs45.8%,P<0.05);但白细胞严重低下<0.5×109/L发生率在化疗后应用升白细胞药物不同时机差异无统计学意义(P>0.05)。结论化疗后尽早应用升白细胞药物,能有效减少感染及白细胞低下的发生。
Objective To analyze the infection and leukopenia of patients with leukemia after different periods of chemotherapy after lung cancer chemotherapy and to find out the suitable timing of leukocyte drugs after chemotherapy. Methods Ninety-eight patients with lung cancer after chemotherapy were randomly divided into two groups: group A (50 cases) started on the second day after chemotherapy, and group B (48 cases) started to use recombinant human granulocyte-colony stimulating factor (G- CSF) Two groups were observed within 2 weeks of co-infection and leukopenia. Results (1) The incidence of infection in group A immediately after chemotherapy was significantly lower than that in group B (10.0% vs 39.6%, P <0.05) at 1 week after chemotherapy. The incidence of leukocyte <3 × 109 / L (P <0.05). However, there was no significant difference in the incidence of <0.5 × 109 / L leukocyte when using leukocyte drug after chemotherapy (P> 0.05). Conclusion The application of as soon as possible after chemotherapy leukocyte drugs, can effectively reduce the incidence of infection and leukopenia.